Generated September 22, 2026 at 8:32 PM ET
· Covers September 22 trading day
· 10 of 177 ready 8-Ks selected
· AI-assisted overview
The day's filings featured significant regulatory and corporate actions: Celldex reported positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria, while Metal Sky Star announced liquidation with shareholder returns. M&A activity included Cognex's $500M acquisition of RealSense, Talos's $420M deepwater asset purchase from Shell, and Progress Software's completed $400M Domo business acquisition. Regulatory updates included Reborn Coffee's Nasdaq delisting notice, FDA clearance for TriSalus's TriNav Advance, and the lifting of a clinical hold on Filana's simufilam. Litigation outcomes included a $15.4M disgorgement award against Beyond Meat and Dalrada's dispute over default demands.
regulatory
negative
materiality 0.80
September 22, 2026, 4:17 PM ET
Reborn Coffee gets Nasdaq delisting notice for low stockholders' equity
- Reported stockholders' equity of $735,642 in June 30 10-Q, below Nasdaq's $2.5M minimum.
- Has until Nov 2, 2026 to submit plan to regain compliance; extension up to 180 days possible.
- Nasdaq closed prior filing deficiency after Sept 14, 2026 10-Q filing; new equity issue remains.
M&A
positive
materiality 0.85
September 22, 2026, 7:01 AM ET
Cognex acquires RealSense for $500M cash to enter robotic perception
- All-cash $500M deal, funded from existing cash/investments; expected to close Q4 2026.
- RealSense 2026 revenue projected at $80-90M, up >50% YoY; robotic perception market ~$600M today, ~$1.6B by 2030.
- Retention: ~$50M in RSUs (vesting 20%/30%/50% over 3 yrs) and up to $69M cash payments (incl. $25M performance-based); press release cites $56.5M target.
M&A
positive
materiality 0.80
September 22, 2026, 4:54 PM ET
Talos closes $420M Shell deepwater asset acquisition in Gulf of America
- Closed purchase of 50% WI and operatorship in Coulomb; 25% WI in BP-operated Na Kika and 4 fields for $420M net cash.
- Decommissioning security of ~$195.5M satisfied via surety bonds; 50% must be cash escrow from Dec 31, 2032.
- Credit facility borrowing base raised to $850M, LC sublimit to $300M; ~$49M in LCs to be issued at closing.
PRGS
PROGRESS SOFTWARE CORP /MA
M&A
positive
materiality 0.80
September 22, 2026, 4:08 PM ET
Progress Software completes $400M acquisition of Domo's AI and data platform business
- Transaction closed Sept 22, 2026; Progress paid $400M cash for substantially all of Domo's AI/data platform assets and certain liabilities.
- Acquisition adds Domo's customer base of over 2,400 businesses and global strategic partners including cloud data warehouse providers.
- Funding from cash on hand and existing revolving credit facility; financial impact to be discussed on Q3 earnings call Sept 30, 2026.
FLNA
FILANA THERAPEUTICS, INC.
regulatory
positive
materiality 0.80
September 22, 2026, 8:00 AM ET
FDA lifts clinical hold on Filana's simufilam, enabling Phase 2a trial for TSC-related epilepsy
- FDA lifted full clinical hold on Filana's IND for simufilam on Sept 22, 2026, enabling Phase 2a trial in TSC-related epilepsy.
- Phase 2a trial: 16-week, randomized, double-blind, two doses, 13 U.S. sites, target 40 subjects aged 12-55; screening expected Q1 2027.
- Company completed trial-readiness during hold: engaged leading CRO, identified sites, recruiting investigators, drug supply in place.
DHTI
Dalrada Technology Group, Inc.
litigation
negative
materiality 0.80
September 22, 2026, 4:58 PM ET
Dalrada disputes IBS default demands of $1.16M and $875K collateral
- IBS declared defaults under financing agreements, demanding $1,162,246 total, including $399,214 ledger losses, $225,000 warrant redemption, $200,000 MGA fee.
- IBS also demanded $875,000 additional collateral under MGA; company notes IBS never funded the $20M/$5M facilities.
- Financing relationships terminated effective Sept. 15, 2026; company disputes all defaults and will defend vigorously.
litigation
negative
materiality 0.80
September 22, 2026, 4:12 PM ET
Beyond Meat hit with $15.4M disgorgement award in trademark case; actual damages cut to $37,500
- Court entered judgment against Beyond Meat totaling $15,437,500, comprising $37,500 actual damages plus $15.4M disgorgement of profits.
- Court reduced jury's $23.5M actual damages to $37,500 but upheld full $15.4M disgorgement of Beyond Meat's profits.
- Court denied Sonate's motions for prejudgment interest and for an increase in the disgorgement award.
TLSI
TriSalus Life Sciences, Inc.
regulatory
positive
materiality 0.65
September 22, 2026, 4:14 PM ET
TriSalus receives FDA clearance for TriNav Advance liver embolization device
- FDA 510(k) clearance for TriNav Advance PEDD device announced Sept 22, 2026; limited market release in coming weeks.
- TriNav Advance adds small-distal-vessel access via compatible microcatheter; two configurations: telescoping and high-flow.
- Expands TriSalus portfolio beyond liver embolization; supports broader range of embolization procedures.
CLDX
Celldex Therapeutics, Inc.
other material
positive
materiality 1.00
September 22, 2026, 7:09 AM ET
Celldex barzolvolimab hits all primary and key secondary endpoints in two Phase 3 CSU trials
- EMBARQ-CSU1/2 met primary endpoint (UAS7) at Week 12; 150mg Q4W change: -20.2 vs placebo -10.7 to -11.4, p<.00001.
- Complete response (UAS7=0) at Week 12: 42-46% on drug vs 9-13% placebo; sustained to Week 24 (45-54% vs 15-18%).
- Omalizumab-refractory subgroup achieved 42-55% complete response at Week 12 vs 9-15% placebo (p≤.009).
MSSAF
Metal Sky Star Acquisition Corp
other material
negative
materiality 0.90
September 22, 2026, 1:27 PM ET
Metal Sky Star SPAC to liquidate, returning ~$16.41/share; last trade Oct 2
- Will not consummate business combination by Oct 4, 2026; intends to liquidate promptly.
- Public shareholders to receive approx $16.41 per share from trust on or about Oct 2, 2026.
- Sponsor waived redemption rights for founder shares and private placement units; no distributions for rights/warrants.